GGrantIndex
Sort

46,585 grants matching heart failure

Epoxyeicosatrienoic acids, diabetes, and cardiovascular disease

$701,774
Rozenn Lemaitre · University Of Washington · R01 · FY2016 · HL

Handoffs and Transitions in Critical Care - Understanding Scalability

$701,730
Meghan Brooks Lane-Fall · University Of Pennsylvania · R01 · FY2022 · HL

4D Multimodal Image-Based Modeling for Bicuspid Aortic Valve Repair Surgery

$701,690
Alison Marie Pouch · University Of Pennsylvania · R01 · FY2023 · HL

Genetic Determinants of Premature Vascular Dysfunction in Families

$701,682
Dhananjay Madhukar Vaidya · Johns Hopkins University · R01 · FY2010 · HL

Multiscale spatiotemporal modeling of cardiac mitochondria

$701,611
William Jonathan Lederer · University Of Maryland Baltimore · U01 · FY2016 · HL

Genetic Markers and gene expression in Kawasaki Disease

$701,575
Jane C Burns · University Of California, San Diego · R01 · FY2007 · HL

CoPARC: Colorado Pulmonary Alcohol Research Collaborative

$701,519
Ellen L Burnham · University Of Colorado Denver · R24 · FY2020 · AA

Resistin regulates NLRP3 inflammasome in pulmonary hypertension

$701,467
Roger A Johns · Johns Hopkins University · R01 · FY2023 · HL

Monitoring Community Trends in Heart Failure

$701,308
Univ Of Massachusetts Med Sch Worcester · R37 · FY2004 · HL

Personalized Risk Prediction to Reduce Cardiovascular Disease in Childhood Cancer Survivors

$701,204
Rebecca Maureen Howell · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA

Factors Associated with Response to Cardiac Resynchronization Therapy in Heart Failure Patients with Non-LBBB ECG Pattern

$701,196
Valentina Kutyifa Valentina Kutyifa Valentina Kutyifa · University Of Rochester · R01 · FY2022 · HL

Chip phosphorylation stimulates the degradation of mutant transthyretin to attenuate cardiac amyloidosis

$701,186
Mark John Ranek · Johns Hopkins University · R01 · FY2024 · HL

Genetic Markers and gene expression in Kawasaki Disease

$701,156
Jane C Burns · University Of California, San Diego · R01 · FY2008 · HL

Cardiovascular Risk of Antiretroviral Therapy Drugs in HIV

$701,122
Jasimuddin Ahamed · Oklahoma Medical Research Foundation · R01 · FY2023 · HL

Targeting cardiovascular events to improve patient outcomes after sepsis

$701,112
Allan J. Walkey · Boston University Medical Campus · R01 · FY2019 · HL

Cardiac Magnetic Resonance for Tissue Characterization Based Risk Stratification of Cardiopulmonary Symptoms, Effort Tolerance, and Prognosis Among COVID-19 Survivors

$701,089
Jiwon Kim · Weill Medical Coll Of Cornell Univ · R01 · FY2025 · HL

Characterization of Coagulation Factor-platelet Interactions: Role of FXI

$701,086
Owen J McCarty · Oregon Health & Science University · R01 · FY2022 · HL

Effects of chronic marijuana use on endothelial function

$701,028
Matthew Lawrence Springer · University Of California, San Francisco · R01 · FY2023 · DA

Feeding Behaviors & Energy Cost in Infants with CHD

$701,026
Barbara S Medoff-Cooper · Children'S Hosp Of Philadelphia · R01 · FY2006 · NR

Mitochondrial Function and Multiomics in Aging-related Disease: Identifying Novel Biomarkers and Causal Relationships

$700,999
Dan E Arking · Johns Hopkins University · R01 · FY2024 · AG

MItochondrial Dysfunction in Cardiac Hypertrophy and Failure

$700,977
Brian O'Rourke · Johns Hopkins University · R01 · FY2010 · HL

Cardiotoxicity in Total Joint Arthroplasty

$700,927
Hilal Maradit Kremers · Mayo Clinic Rochester · R01 · FY2022 · HL

Cardiotoxicity in Total Joint Arthroplasty

$700,927
Hilal Maradit Kremers · Mayo Clinic Rochester · R01 · FY2020 · HL

Cardiotoxicity in Total Joint Arthroplasty

$700,927
Hilal Maradit Kremers · Mayo Clinic Rochester · R01 · FY2019 · HL

Cardiotoxicity in Total Joint Arthroplasty

$700,927
Hilal Maradit Kremers · Mayo Clinic Rochester · R01 · FY2021 · HL